Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
83 hedge funds and large institutions have $474M invested in Regulus Therapeutics in 2014 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 6 closing their positions.
617% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 6
376% more capital invested
Capital invested by funds: $99.6M → $474M (+$374M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
69% more funds holding
Funds holding: 49 → 83 (+34)
48% more call options, than puts
Call options by funds: $9.49M | Put options by funds: $6.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$70.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$40.4M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$33.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$16.2M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$10.6M |
| 2 |
Goldman Sachs
New York
|
-$3.14M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$2.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.31M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$1.26M |
RGLS Hedge Fund Activity: Q4 2014 in Review
83 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2014, worth a combined $474M — up 376% from $99.6M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new RGLS positions and 6 closed out — a net gain of 37 holders — while 21 added to existing stakes and 12 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $70.3M. The largest seller was HealthCor Management, exiting entirely with an estimated $10.6M sold.
- 83 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2014, up from 49 in Q3 2014.
- Funds reported $474M of Regulus Therapeutics stock for Q4 2014, up 376% quarter-over-quarter.
- 43 funds opened new Regulus Therapeutics positions in Q4 2014 and 6 closed out, a net change of +37 holders.
- The largest Regulus Therapeutics buyer in Q4 2014 was RA Capital Management, an estimated $70.3M added.
- The largest Regulus Therapeutics seller in Q4 2014 was HealthCor Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q4 2014.